INTRODUCTION: Chronic kidney disease (CKD) is a major public health issue in the USA. Identification of monogenic causes of CKD, which are present in ∼10% of adult cases, can impact prognosis and patient management. Broad gene panels can provide unbiased testing approaches, which are advantageous in phenotypically heterogeneous diseases. However, the use and yield of broad genetic panels by nephrologists in clinical practice is not yet well characterized. METHODS: Renal genetic testing, ordered exclusively for clinical purposes, predominantly by general and transplant nephrologists within the USA, was performed on 1,007 consecutive unique patient samples. Testing was performed using a commercially available next-generation sequencing-based 382 gene kidney disease panel. Pathogenic (P) and likely pathogenic (LP) variants were reported. Positive findings included a monoallelic P/LP variant in an autosomal dominant or X-linked gene and biallelic P/LP variants in autosomal recessive genes. RESULTS: Positive genetic findings were identified in 21.1% (212/1,007) of cases. A total of 220 positive results were identified across 48 genes. Positive results occurred most frequently in the PKD1 (34.1%), COL4A5 (10.9%), PKD2 (10.0%), COL4A4 (6.4%), COL4A3 (5.9%), and TTR (4.1%) genes. Variants identified in the remaining 42 genes comprised 28.6% of the total positive findings, including single positive results in 26 genes. Positive results in >1 gene were identified in 7.5% (16/212) of cases. CONCLUSIONS: Use of broad panel genetic testing by clinical nephrologists had a high success rate, similar to results obtained by academic centers specializing in genetics.

Division of Nephrology and Hypertension Department of Medicine University of Utah Salt Lake City Utah USA

Florida Kidney Physicians Boca Raton Florida USA

Fulgent Genetics Temple City California USA

MUSC Lancaster Lancaster South Carolina USA

Natera Inc San Carlos California USA

North Carolina Nephrology Associates Cary North Carolina USA

Research Unit for Rare Diseases Department of Pediatrics and Adolescent Medicine 1st Faculty of Medicine Charles University Prague Czechia

Section on Nephrology Wake Forest School of Medicine Winston Salem North Carolina USA

Zobrazit více v PubMed

Centers for Disease Control and Prevention: Chronic Kidney Disease in the United States. 2019. [Available from: https://www.cdc.gov/kidneydisease/pdf/2019_National-Chronic-Kidney-Disease-Fact-Sheet.pdf] (accessed March 31, 2021)

Vivante A, Skorecki K. Introducing routine genetic testing for patients with CKD. Nat Rev Nephrol. 2019;15((6)):321–2. PubMed

Groopman EE, Marasa M, Cameron-Christie S, Petrovski S, Aggarwal VS, Milo-Rasouly H, et al. Diagnostic utility of exome sequencing for kidney disease. N Engl J Med. 2019;380((2)):142–51. PubMed PMC

Jayasinghe K, Quinlan C, Mallett AJ, Kerr PG, McClaren B, Nisselle A, et al. Attitudes and practices of Australian nephrologists toward implementation of clinical genomics. Kidney Int Rep. 2021;6((2)):272–83. PubMed PMC

Lata S, Marasa M, Li Y, Fasel DA, Groopman E, Jobanputra V, et al. Whole-exome sequencing in adults with chronic kidney disease: a pilot study. Ann Intern Med. 2018;168((2)):100–9. PubMed PMC

Connaughton DM, Kennedy C, Shril S, Mann N, Murray SL, Williams PA, et al. Monogenic causes of chronic kidney disease in adults. Kidney Int. 2019;95((4)):914–28. PubMed PMC

Snoek R, van Jaarsveld RH, Nguyen TQ, Peters EDJ, Elferink MG, Ernst RF, et al. Genetics-first approach improves diagnostics of ESKD patients younger than 50 years. Nephrol Dial Transplant. 2022;37((2)):349–57. PubMed

Murray SL, Dorman A, Benson KA, Connaughton DM, Stapleton CP, Fennelly NK, et al. Utility of genomic testing after renal biopsy. Am J Nephrol. 2020;51((1)):43–53. PubMed PMC

Schrezenmeier E, Kremerskothen E, Halleck F, Staeck O, Liefeldt L, Choi M, et al. The underestimated burden of monogenic kidney disease in adults waitlisted for kidney transplantation. Genet Med. 2021;23((7)):1219–24. PubMed PMC

Jayasinghe K, Stark Z, Kerr PG, Gaff C, Martyn M, Whitlam J, et al. Clinical impact of genomic testing in patients with suspected monogenic kidney disease. Genet Med. 2021;23((1)):183–91. PubMed PMC

Mansilla MA, Sompallae RR, Nishimura CJ, Kwitek AE, Kimble MJ, Freese ME, et al. Targeted broad-based genetic testing by next-generation sequencing informs diagnosis and facilitates management in patients with kidney diseases. Nephrol Dial Transplant. 2021;36((2)):295–305. PubMed PMC

Lee CY, Yen HY, Zhong AW, Gao H. Resolving misalignment interference for NGS-based clinical diagnostics. Hum Genet. 2021;140((3)):477–92. PubMed

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17((5)):405–24. PubMed PMC

Savige J, Storey H, Watson E, Hertz JM, Deltas C, Renieri A, et al. Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria. Eur J Hum Genet. 2021;29((8)):1186–97. PubMed PMC

Clinical Genome Resource: Kidney Disease CDWG 2021. [Available from: https://clinicalgenome.org/working-groups/clinical-domain/clingen-kidney-disease-clinical-domain-working-group/] (accessed January 20, 2021)

Albertus P, Morgenstern H, Robinson B, Saran R. Risk of ESRD in the United States. Am J Kidney Dis. 2016;68((6)):862–72. PubMed PMC

Naik RP, Derebail VK, Grams ME, Franceschini N, Auer PL, Peloso GM, et al. Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA. 2014;312((20)):2115–25. PubMed PMC

Mallawaarachchi AC, Lundie B, Hort Y, Schonrock N, Senum SR, Gayevskiy V, et al. Genomic diagnostics in polycystic kidney disease: an assessment of real-world use of whole-genome sequencing. Eur J Hum Genet. 2021;29((5)):760–70. PubMed PMC

Cornec-Le Gall E, Audrezet MP, Rousseau A, Hourmant M, Renaudineau E, Charasse C, et al. The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27((3)):942–51. PubMed PMC

Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, et al. A Practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol. 2018;29((10)):2458–70. PubMed PMC

Warady BA, Agarwal R, Bangalore S, Chapman A, Levin A, Stenvinkel P, et al. Alport syndrome classification and management. Kidney Med. 2020;2((5)):639–49. PubMed PMC

Kashtan CE, Ding J, Garosi G, Heidet L, Massella L, Nakanishi K, et al. Alport syndrome: a unified classification of genetic disorders of collagen IV alpha345: a position paper of the alport syndrome classification working group. Kidney Int. 2018;93((5)):1045–51. PubMed

Vivante A, Chacham OS, Shril S, Schreiber R, Mane SM, Pode-Shakked B, et al. Dominant PAX2 mutations may cause steroid-resistant nephrotic syndrome and FSGS in children. Pediatr Nephrol. 2019;34((9)):1607–13. PubMed PMC

Bedin M, Boyer O, Servais A, Li Y, Villoing-Gaude L, Tete MJ, et al. Human C-terminal CUBN variants associate with chronic proteinuria and normal renal function. J Clin Invest. 2020;130((1)):335–44. PubMed PMC

Foster MC, Coresh J, Fornage M, Astor BC, Grams M, Franceschini N, et al. APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol. 2013;24((9)):1484–91. PubMed PMC

Naik RP, Irvin MR, Judd S, Gutierrez OM, Zakai NA, Derebail VK, et al. Sickle Cell Trait and the Risk of ESRD in Blacks. J Am Soc Nephrol. 2017;28((7)):2180–7. PubMed PMC

United States Renal Data System . 2020 USRDS annual data report: epidemiology of kidney disease in the United States. Bethesda, MD, USA: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2020.

Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997;336((7)):466–73. PubMed

Lobato L, Rocha A. Transthyretin amyloidosis and the kidney. Clin J Am Soc Nephrol. 2012;7((8)):1337–46. PubMed

Olaniran KO, Allegretti AS, Zhao SH, Achebe MM, Eneanya ND, Thadhani RI, et al. Kidney function decline among black patients with sickle cell trait and sickle cell disease: an observational cohort study. J Am Soc Nephrol. 2020;31((2)):393–404. PubMed PMC

Centers for Disease Control and Prevention: Data & Statistics on Sickle Cell Disease 2020. [Available from: https://www.cdc.gov/ncbddd/sicklecell/data.html] (accessed April 20, 2021)

Bleyer AJ, Kidd K, Robins V, Martin L, Taylor A, Santi A, et al. Outcomes of patient self-referral for the diagnosis of several rare inherited kidney diseases. Genet Med. 2020;22((1)):142–9. PubMed PMC

Devuyst O, Olinger E, Weber S, Eckardt KU, Kmoch S, Rampoldi L, et al. Autosomal dominant tubulointerstitial kidney disease. Nat Rev Dis Primers. 2019;5((1)):60. PubMed

Mrug M, Bloom MS, Seto C, Malhotra M, Tabriziani H, Gauthier P, et al. Genetic testing for chronic kidney diseases: clinical utility and barriers perceived by nephrologists. Kidney Med. 2021;3((6)):1050–6. PubMed PMC

Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46((D1)):D1062–7. PubMed PMC

Autosomal dominant tubulointerstitial kidney disease: A review